Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: Effect of EBV infection of breast cancer cells on resistance to paclitaxel (taxol)

Journal of Virology

Volumn 80, Issue 2, 2006, Pages 845-853

  Arbach, Hratch ^a   Viglasky, Viktor ^a,g   Lefeu, Florence ^a   Guinebretière, Jean Marc ^b   Ramirez, Vanessa ^a   Bride, Nadège ^a   Boualaga, Nadia ^a   Bauchet, Thomas ^a   Peyrat, Jean Philippe ^c   Mathieu, Marie Christine ^e   Mourah, Samia ^a   Podgorniak, Marie Pierre ^a   Seignerin, Jean Marie ^d   Takada, Kenzo ^f   Joab, Irène ^a  

^a INSERM   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d UNIV GRENOBLE ALPES   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f HOKKAIDO UNIVERSITY   (Japan)

^g Faculty of Natural Sciences   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; ONCOPROTEIN; PACLITAXEL; RNA; VIRUS DNA;

ADULT; AGED; ARTICLE; BARF 1 GENE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER TISSUE; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; EBNA 1 GENE; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE NUMBER; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LASER CAPTURE MICRODISSECTION; LMP 1 GENE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; TUMOR CELL; VIRUS GENE; VIRUS GENOME; VIRUS INFECTION; VIRUS LOAD;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOPSY; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA, VIRAL; DRUG RESISTANCE, NEOPLASM; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; GENE EXPRESSION; GENES, MDR; HERPESVIRUS 4, HUMAN; HUMANS; MIDDLE AGED; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, VIRAL; VIRAL PROTEINS;

DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 30344458825     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.80.2.845-853.2006     Document Type: Article

References (46)

1. Baker, E. K., R. W. Johnstone, J. R. Zalcberg, and A. El-Osta. 8 August 2005. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 10.1038/sj.onc.1208955.
2. Blankenstein, M. A. 1990. Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols. Experience of the E.O.R.T.C. Receptor Group. Breast Cancer Res. Treat. 17:91-98.
3. Bonnet, M., J. M. Guinebretiere, E. Kremmer, V. Grunewald, E. Benhamou, G. Contesso, and I. Joab. 1999. Detection of Epstein-Barr virus in invasive breast cancers. J. Natl. Cancer Inst. 91:1376-1381.
4. Brengel-Pesce, K., P. Morand, A. Schmuck, M. J. Bourgeat, M. Buisson, G. Bargues, M. Bouzid, and J. M. Seigneurin. 2002. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. J. Med. Virol. 66:360-369.
5. Cailleau, R., R. Young, M. Olive, and W. J. Reeves, Jr. 1974. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53:661-674.
6. Chu, P. G., K. L. Chang, Y. Y. Chen, W. G. Chen, and L. M. Weiss. 2001. No significant association of Epstein-Barr virus infection with invasive breast carcinoma. Am. J. Pathol. 159:571-578.
7. Cochet, C., D. Martel-Renoir, V. Grunewald, J. Bosq, G. Cochet, G. Schwaab, J. F. Bernaudin, and I. Joab. 1993. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 197:358-365.
8. Contesso, G., H. Mouriesse, S. Friedman, J. Genin, D. Sarrazin, and J. Rouesse. 1987. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J. Clin. Oncol. 5:1378-1386.
9. Deshpande, C. G., S. Badve, N. Kidwai, and R. Longnecker. 2002. Lack of expression of the Epstein-Barr virus (EBV) gene products, EBERs, EBNA1, LMP1, and LMP2A, in breast cancer cells. Lab. Investig. 82:1193-1199.
10. Fina, F., S. Romain, L. Ouafik, J. Palmari, F. Ben Ayed, S. Benharkat, P. Bonnier, F. Spyratos, J. A. Foekens, C. Rose, M. Buisson, H. Gerard, M. O. Reymond, J. M. Seigneurin, and P. M. Martin. 2001. Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas. Br. J. Cancer 84:783-790.
11. Glockner, S., H. Buurman, W. Kleeberger, U. Lehmann, and H. Kreipe. 2002. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab. Investig. 82:1419-1426.
12. Grunewald, V., M. Bonnet, S. Boutin, T. Yip, H. Louzir, M. Levrero, J. M. Seigneurin, M. Raphael, R. Touitou, D. Martel-Renoir, C. Cochet, A. Durandy, P. Andre, W. Lau, Y. Zeng, and I. Joab. 1998. Amino-acid change in the Epstein-Barr-virus ZEBRA protein in undifferentiated nasopharyngeal carcinomas from Europe and North Africa. Int. J. Cancer 75:497-503.
13. Gutsch, D. E., E. A. Holley-Guthrie, Q. Zhang, B. Stein, M. A. Blanar, A. S. Baldwin, and S. C. Kenney. 1994. The bZIP transactivator of Epstein-Barr viras, BZLF1, functionally and physically interacts with the p65 subunit of NF-κB. Mol. Cell. Biol. 14:1939-1948.
14. Herrmann, K., and G. Niedobitek. 2003. Lack of evidence for an association of Epstein-Barr virus infection with breast carcinoma. Breast Cancer Res. 5:R13-R17.
15. Huang, J., H. Chen, L. Hutt-Fletcher, R. F. Ambinder, and S. D. Hayward. 2003. Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. J. Virol. 77:13267-13274.
16. Imai, S., J. Nishikawa, and K. Takada. 1998. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J. Virol. 72:4371-4378.
17. Inman, G. J., U. K. Binne, G. A. Parker, P. J. Farrell, and M. J. Allday. 2001. Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death. J. Virol. 75:2400-2410.
18. Kieff, E., and A. B. Rickinson. 2001. Epstein-Barr virus and its replication, p. 2531-2536. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 4th ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, Pa.
19. Labrecque, L. G., D. M. Barnes, I. S. Fentiman, and B. E. Griffin. 1995. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res. 55:39-45.
20. Landegren, U. 1984. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J. Immunol. Methods 67:379-388.
21. Lawrence, J. B., C. A. Villnave, and R. H. Singer. 1988. Sensitive, high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line. Cell 52:51-61.
22. Li, Y., J. Webster-Cyriaque, C. C. Tomlinson, M. Yohe, and S. Kenney. 2004. Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression. J. Virol. 78:4197-4206.
23. Luqmani, A., and S. Shousha. 1995. Presence of Epstein-Barr virus in breast carcinoma. Int. J. Oncol. 6:899-903.
24. Menashi, S., M. Serova, L. Ma, S. Vignot, S. Mourah, and F. Calvo. 2003. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res. 63:7575-7580.
25. Miyashita, E. M., B. Yang, K. M. Lam, D. H. Crawford, and D. A. Thorley-Lawson. 1995. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80:593-601.
26. Murono, S., H. Inoue, T. Tanabe, I. Joab, T. Yoshizaki, M. Furukawa, and J. S. Pagano. 2001. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc. Natl. Acad. Sci. USA 98:6905-6910.
27. Murray, P. G., D. Lissauer, J. Junying, G. Davies, S. Moore, A. Bell, J. Timms, D. Rowlands, C. McConkey, G. M. Reynolds, S. Ghataura, D. England, R. Caroll, and L. S. Young. 2003. Reactivity with a monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. Cancer Res. 63:2338-2343.
28. Murray, P. G., G. Niedobitek, E. Kremmer, F. Grasser, G. M. Reynolds, A. Cruchley, D. M. Williams, N. Muller-Lantzsch, and L. S. Young. 1996. In situ detection of the Epstein-Barr virus-encoded nuclear antigen 1 in oral hairy leukoplakia and virus-associated carcinomas. J. Pathol. 178:44-47.
29. Ooka, T. 2001. BARF-1 gene as an EBV encoded oncogene. Epstein-Barr Virus Rep. 8:177-182.
30. Orr, G. A., P. Verdier-Pinard, H. McDaid, and S. Band Horwitz. 2003. Mechanisms of Taxol resistance related to microtubules. Oncogene 22:7280-7295.
31. Pawlowski, V., F. Revillion, M. Hebbar, L. Hornez, and J. P. Peyrat. 2000. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res. 6:4217-4225.
32. Perrigoue, J. G., J. A. den Boon, A. Friedl, M. A. Newton, P. Ahlquist, and B. Sugden. 2005. Lack of association between EBV and breast carcinoma. Cancer Epidemiol. Biomark. Prev. 14:809-814.
33. Rickinson, A. B., and E. Kieff. 2001. Epstein-Barr virus, p. 2594-2611. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 4th ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, Pa.
34. Swenson, J. J., A. E. Mauser, W. K. Kaufmann, and S. C. Kenney. 1999. The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction. J. Virol. 73:6540-6550.
35. Tada, Y., M. Wada, K. Kuroiwa, N. Kinugawa, T. Harada, J. Nagayama, M. Nakagawa, S. Naito, and M. Kuwano. 2000. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin. Cancer Res. 6:4618-4627.
36. Talvensaari-Mattila, A., P. Paakko, and T. Turpeenniemi-Hujanen. 2003. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br. J. Cancer 89:1270-1275.
37. Touitou, R., H. Arbach, C. Cochet, J. Feuillard, A. Martin, M. Raphael, and I. Joab. 2003. Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines. J. Gen. Virol. 84:949-957.
38. Tsutsui, S., S. Obno, S. Murakami, A. Kataoka, J. Kinoshita, and Y. Hachitanda. 2002. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. Eur. J. Surg. Oncol. 28:383-387.
39. van Netten, J. P., I. G. Thornton, S. J. Carlyle, M. L. Brigden, P. Coy, N. L. Goodchild, S. Gallagher, and E. J. George. 1987. Multiple microsample analysis of intratumor estrogen receptor distribution in breast cancers by a combined biochemical/immunohistochemical method. Eur. J. Cancer Clin. Oncol. 23:1337-1342.
40. Wakisaka, N., S. Murono, T. Yoshizaki, M. Furukawa, and J. S. Pagano. 2002. Epstein-Barr virus latent membrane protein 1 induces and causes release of fibroblast growth factor-2. Cancer Res. 62:6337-6344.
41. Wakisaka, N., and J. S. Pagano. 2003. Epstein-Barr virus induces invasion and metastasis factors. Anticancer Res. 23:2133-2138.
42. Xue, S. A., I. A. Lampert, J. S. Haldane, J. E. Bridger, and B. E. Griffin. 2003. Epstein-Barr virus gene expression in human breast cancer: protagonist or passenger? Br. J. Cancer 89:113-119.
43. Yague, E., A. L. Armesilla, G. Harrison, J. Elliott, A. Sardini, C. F. Higgins, and S. Raguz. 2003. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J. Biol. Chem. 278:10344-10352.
44. Yoshizaki, T., H. Sato, S. Murono, J. S. Pagano, and M. Furukawa. 1999. Matrix metalloproteinase 9 is induced by the Epstein-Barr virus BZLF1 transactivator. Clin. Exp. Metastasis 17:431-436.
45. Young, L. S., and P. G. Murray. 2003. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22:5108-5121.
46. Zhang, Q., D. Gutsch, and S. Kenney. 1994. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol. Cell. Biol. 14:1929-1938.